hemotune raises CHF 7.25 million Series B1 funding

26-04-2022 – hemotune announced the closing of a CHF 7.25 million Series B1 for the development of HemoSystem, a breakthrough blood purification platform based on nanoengineered magnetic beads.

Lukas Langenegger with the HemoDevice

The Series B1 financing round is composed of an investment consortium led by OCCIDENT with the participation of all previous investors, including Zürcher Kantonalbank, and joined by the new investors HEMEX, VP Venture Partners, as well as a global family office, and private individuals. The Series B1 will allow hemotune to complete the preclinical development of HemoSystem and prepare a clinical trial in hemotune’s lead indication.